Antifungal activity of statins;L'activité antifongique des statines

Journal de Mycologie Medicale

Volumn 20, Issue 3, 2010, Pages 212-217

  Lefebvre, M ^a   Alshawa, K ^b   Dupont, B ^c  

^a HÔTEL DIEU   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Antifungal; Aspergillus; Candida; Statins; Zygomycete

Indexed keywords

EID: 77956615198     PISSN: 11565233     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mycmed.2010.05.007     Document Type: Review

References (36)

1. Agarwal B., Bhendwal S., Halmos B., Moss S.F., Ramey W.G., Holt P.R. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 1999, 5:2223-2229.
2. Chamilos G., Lewis R.E., Kontoyiannis D.P. Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole. Antimicrob Agents Chemother 2006, 50:96-103.
3. Chin N.X., Weitzman I., Della-Latta P. In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with flucanazole and itraconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother 1997, 41:850-852.
4. Cornillet A., Camus C., Nimubona S., Gandemer V., Tattevin P., Belleguic C., et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 2006, 43:577-584.
5. Falagas M.E., Makris G.C., Matthaiou D.K., Rafailidis P.I. Statins for infection and sepsis: a systematic review of the clinical evidence. J Antimicrob Chemother 2008, 61:774-785.
6. Galgóczy L., Papp T., Vágvölgyi C. In vitro interaction between suramin and fluvastatin against clinically important zygomycetes. Mycoses 2009, 52:447-453.
7. Gyetvai A., Emri T., Takács K., Dergez T., Fekete A., Pesti M., et al. Lovastatin possesses a fungistatic effect against Candida albicans, but does not trigger apoptosis in this opportunistic human pathogen. FEMS Yeast Res 2006, 6:1140-1148.
8. Home - ClinicalTrials.gov [Internet]. Available from: [cité 2010]. http://clinicaltrials.gov/.
9. Kim W.S., Kim M.M., Choi H.J., Yoon S.S., Lee M.H., Park K., et al. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 2001, 19:81-83.
10. Kontoyiannis D.P. Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: a hypothesis. Clin Infect Dis 2007, 44:1089-1090.
11. Kopack A.M., Forrest G. Effects of HMG CoA reductase inhibitors (statins) on patients with candidemia. Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy 2006, M-908.
12. Kopterides P., Falagas M.E. Statins for sepsis: a critical and updated review. Clin Microbiol Infect 2009, 15:325-334.
13. Larner J., Jane J., Laws E., Packer R., Myers C., Shaffrey M. A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol 1998, 21:579-583.
14. Lass-Flörl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 2009, 52:197-205.
15. Lorenz R.T., Parks L.W. Effects of lovastatin (mevinolin) on sterol levels and on activity of azoles in Saccharomyces cerevisiae. Antimicrob Agents Chemother 1990, 34:1660-1665.
16. Lukács G., Papp T., Nyilasi I., Nagy E., Vágvölgyi C. Differentiation of Rhizomucor species on the basis of their different sensitivities to lovastatin. J Clin Microbiol 2004, 42:5400-5402.
17. Macreadie I.G., Johnson G., Schlosser T., Macreadie P.I. Growth inhibition of Candida species and Aspergillus fumigatus by statins. FEMS Microbiol Lett 2006, 262:9-13.
18. Manzoni M., Rollini M. Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs. Appl Microbiol Biotechnol 2002, 58:555-564.
19. März W., Köenig W. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?. J Cardiovasc Risk 2003, 10:169-179.
20. Nash J.D., Burgess D.S., Talbert R.L. Effect of fluvastatin and pravastatin, HMG-CoA reductase inhibitors, on fluconazole activity against Candida albicans. J Med Microbiol 2002, 51:105-109.
21. Natesan S.K., Chandrasekar P.H., Alangaden G.J., Manavathu E.K. Fluvastatin potentiates the activity of caspofungin against Aspergillus fumigatus in vitro. Diagn Microbiol Infect Dis 2008, 60:369-373.
22. Neuvonen P.J., Backman J.T., Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet 2008, 47:463-474.
23. Nucci M. Emerging moulds: Fusarium, Scedosporium and zygomycetes in transplant recipients. Curr Opin Infect Dis 2003, 16:607-612.
24. Qiao J., Kontoyiannis D.P., Wan Z., Li R., Liu W. Antifungal activity of statins against Aspergillus species. Med Mycol 2007, 45:589-593.
25. Rikitake Y., Hirata K. Inhibition of RhoA or Rac1? Mechanism of cholesterol-independent beneficial effects of statins. Circ J 2009, 73:231-232.
26. Roden M.M., Zaoutis T.E., Buchanan W.L., Knudsen T.A., Sarkisova T.A., Schaufele R.L., et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005, 41:634-653.
27. Roze L.V., Linz J.E. Lovastatin triggers an apoptosis-like cell death process in the fungus Mucor racemosus. Fungal Genet Biol 1998, 25:119-133.
28. Sun H., Singh N. Antimicrobial and immunomodulatory attributes of statins: relevance in solid-organ transplant recipients. Clin Infect Dis 2009, 48:745-755.
29. Terblanche M., Almog Y., Rosenson R.S., Smith T.S., Hackam D.G. Statins: panacea for sepsis?. Lancet Infect Dis 2006, 6:242-248.
30. Terblanche M., Almog Y., Rosenson R.S., Smith T.S., Hackam D.G. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis 2007, 7:358-368.
31. Thibault A., Samid D., Tompkins A.C., Figg W.D., Cooper M.R., Hohl R.J., et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996, 2:483-491.
32. Tleyjeh I.M., Kashour T., Hakim F.A., Zimmerman V.A., Erwin P.J., Sutton A.J., et al. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 2009, 169:1658-1667.
33. Tortorano A.M., Peman J., Bernhardt H., Klingspor L., Kibbler C.C., Faure O., et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004, 23:317-322.
34. Vaughan C.J., Gotto A.M. Update on statins: 2003. Circulation 2004, 110:886-892.
35. Westermeyer C., Macreadie I.G. Simvastatin reduces ergosterol levels, inhibits growth and causes loss of mtDNA in Candida glabrata. FEMS Yeast Res 2007, 7:436-441.
36. Yang Y., Huang W., Chuan L., Xiao D., Zeng Y., Zhou D., et al. In vitro and in vivo study of cell growth inhibition of simvastatin on chronic myelogenous leukemia cells. Chemotherapy 2008, 54:438-446.